AXLRx Book a callCommission

Big Pharma · Company profile

Merck

Commission a Merck report

By therapy area

Therapy area All areas Oncology

AXLRx reports featuring Merck

CI · Oncology · CI Team · Launch Lead US NSCLC Competitive Intelligence Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry. US · In-Market · Read report → DL · Oncology · CI Team · Medical Affairs US NSCLC Disease Landscape US NSCLC segments by histology and biomarker before it segments by drug. This maps where patients are actually diagnosed and tested, and where the gap between diagnosis and treatment costs them. US · In-Market · Read report → P&HTA · Oncology · Market Access · Medical Affairs US NSCLC Payer & HTA CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%. But PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers. US · In-Market · Read report →